Carbiotix Launches Second Generation Diagnostic Platform
Feb 11, 2020, 03:01 ET
STOCKHOLM, Feb. 11, 2020 /PRNewswire/ -- Carbiotix (publ) ("Carbiotix") announces today that the company has launched its second generation diagnostic platform for gut health based on Next Generation Sequencing (NGS). The company will now offer a NGS test with three samples as a standard and at a cost that is 1/3 the cost of the nearest competitor on the market per sample. Carbiotix will leverage this transformational competitive advantage and target the entire market for consumer and clinical microbiome diagnostic services valued at over 800 million Euro per annum.
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
CONTACT:
Carbiotix AB
Kristofer Cook, CEO
Tel: 0708-796580
E-mail: kristofer.cook@carbiotix.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Carbiotix
